AN2 Therapeutics , Inc. (NASDAQ:ANTX), currently trading at $1.23 and showing a significant 93.54% decline over the past year, has undergone a strategic shift following disappointing results from its ...
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...
Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry ...
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112188096/en/ The articles, information, and content displayed on this webpage ...
Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraborole Observational Study funded by the National ...
Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028 MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (ANTX), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback